Uploaded February 2025 | Updated September 2026, 1 week ago
DOI: 10.14336/AD.2024.1492
When AI meets robots, the force combine. We’re thrilled to announce the publication of our latest breakthrough: "AI-driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent."
INS018-055 It has demonstrated remarkable potential across clinical trials—successfully completing Phase 0, two Phase I studies, and one Phase IIa study for IPF treatment, as well as numerous indication expansion experiments.
In our fully-automated robotic lab, it was revealed to act as a potent senomorphic agent. Notably, it outperformed Rapamycin in reducing key cellular senescence markers, all while preserving cell viability—a crucial factor in advancing safe and effective longevity therapeutics.
This milestone not only validates the power of our integrated, AI-driven approach but also marks an important leap forward in rethinking treatments for age-related diseases. A heartfelt congratulations to our brilliant and dedicated team for making this possible!
DOI: 10.14336/AD.2024.1492
Be sure to check out the full details in our paper, available now, and join us as we continue to set new standards in drug discovery and longevity research.
DOI: 10.14336/AD.2024.1492
When AI meets robots, the force combine. We’re thrilled to announce the publication of our latest breakthrough: "AI-driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent."
INS018-055 It has demonstrated remarkable potential across clinical trials—successfully completing Phase 0, two Phase I studies, and one Phase IIa study for IPF treatment, as well as numerous indication expansion experiments.
In our fully-automated robotic lab, it was revealed to act as a potent senomorphic agent. Notably, it outperformed Rapamycin in reducing key cellular senescence markers, all while preserving cell viability—a crucial factor in advancing safe and effective longevity therapeutics.
This milestone not only validates the power of our integrated, AI-driven approach but also marks an important leap forward in rethinking treatments for age-related diseases. A heartfelt congratulations to our brilliant and dedicated team for making this possible!
DOI: 10.14336/AD.2024.1492
Be sure to check out the full details in our paper, available now, and join us as we continue to set new standards in drug discovery and longevity research.
